Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients with MSI-H or dMMR mCRC By Ogkologos - December 9, 2024 770 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Opinion: ‘We’re speaking with One Cancer Voice, but is anyone listening?’ March 16, 2021 2026 Heine H. Hansen Award Recipient Announced February 3, 2026 Are New Immune-Based Treatments for Kidney and Pancreatic Cancer on the... April 23, 2025 Osimertinib After Definitive Chemoradiotherapy Prolongs PFS in Patients with Unresectable Stage... June 6, 2024 Load more HOT NEWS FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for NSCLC with EGFR... Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients... Talking About Sexual Health Concerns With Your Cancer Care Team: How... Opportunity and mentorship: Our new PhD programme aiming to open-up academia...
